Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated. The

Trial Details

NCT ID
NCT06305299
Phase
PHASE1
Sponsor
UNC Lineberger Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • iC9-CAR.B7-H3 T cells
  • Cyclophosphamide
  • Fludarabine
Locations (sample)
  • Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

  • Unless otherwise noted, subjects must meet all of the following criteria to participate in all phases of the study:
  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information e…
  • Age ≥ 18 years at the time of consent.
  • Eastern Cooperative Oncology Group (ECOG) of 0-2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →